Tech Company Financing Transactions
Talus Bioscience Funding Round
Talus Bioscience closed a $11.2 million funding round on 8/20/2024. Investors included Two Bear Capital, BoxOne Ventures and FundersClub.
Transaction Overview
Company Name
Announced On
8/20/2024
Transaction Type
Venture Equity
Amount
$11,200,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its therapeutic programs, which include Brachyury-driven cancers and an undruggable transcription factor implicated in prostate cancer.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
550 17th Ave 550
Seattle, WA 98122
USA
Seattle, WA 98122
USA
Phone
Website
Email Address
Overview
Talus Bioscience is unlocking transcription factor therapeutics for cancer and beyond. Our highly interdisciplinary team are pioneers in proteomics-first drug discovery for transcription factors, with more than 6,800 citations, 50% PhD scientists, and two "40-under-40" proteomicists.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alex Federation
Chief Operating Officer
Michelle Briscoe
Chief Technical Officer
Lindsay Pino
VP - Administration
Kyle Siebenthall
VP - Engineering
Will Fondrie
Browse more venture capital transactions:
Prev: 8/20/2024: Gradient Labs venture capital transaction
Next: 8/20/2024: Reliant AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs